NovioSense BV

NovioSense BV is a Medical Devices company founded in 2012 and headquartered in The Netherlands. It is a spin out company from Fraunhofer Gesellschaft and NovioTech BV based in Nijmegen. NovioSense focuses on developing a wireless platform technology for non-invasive monitoring of disease biomarkers. The company's first sensor, a wireless non-invasive glucose sensor, is based on the NovioSense technology. The development is aimed at creating a clinical prototype for non-invasive continuous monitoring of glucose levels in tear fluid. The company's most recent funding round was a Series D investment on 24 October 2016, with participation from Fraunhofer Venture, NovioTech, and Topfonds Gelderland.